July 31, 2026
Perseus Proteomics Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Presentation Accepted for the 85th Annual Meeting of the Japanese Cancer Association

Perseus Proteomics Inc. (“Perseus Proteomics”) is pleased to announce that the results of its joint research with UBE Corporation (Head Office: Minato-ku, Tokyo; President and Representative Director: Yuki Nishida) have been accepted for presentation in a poster session at the 85th Annual Meeting of the Japanese Cancer Association, to be held from September 24 to 26, 2026.

At the Annual Meeting, Perseus Proteomics will present favorable nonclinical data suggesting that PPMX-T004b-PGAP-1 has a differentiated profile compared with another antibody-drug conjugate currently in development, as well as its future potential.

Presentation title:
Characterization of the Novel CDH3-Targeting Antibody-Drug Conjugate PPMX-T004b-PGAP-1 in a Comparison with Prior Antibody-Drug Conjugates

Authors:
Sayuri Kaneko*, Hiroko Akiyoshi*, Shimpei Nonouchi**, Takashi Matsushita**, Takamasa Kashiwagi**, Gen Mizuno**, Yukinori Wada**, Megumi Hikichi*, Yoichi Aikawa*, Shinji Hagiwara*
*Perseus Proteomics Inc.
**UBE Corporation

Presentation date and time:
September 24, 2026, afternoon (scheduled)

Venue:
Kyoto International Conference Center

About PPMX-T004b-PGAP-1
PPMX-T004b-PGAP-1 is an antibody-drug conjugate (ADC) targeting cadherin 3 (CDH3), which is highly expressed in many solid tumors such as ovarian cancer, biliary tract cancer, and head and neck squamous cell carcinoma. It is one of the PPMX-T004 candidates currently being developed as ADCs and is being optimized to balance efficacy and toxicity.

About the Japanese Cancer Association
The Japanese Cancer Association was established to contribute to the advancement of cancer research by promoting research presentations and knowledge exchange on the

science of cancer and its applications, as well as collaboration among members and with related academic societies in Japan and overseas. Through these activities, the Association aims to advance academic research, improve cancer treatment, and contribute to public health and welfare.